SynthesisScience translational medicine2020

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.

Jonas Bovijn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.